If you have been reading about wound model and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-02-11. Numbers and descriptions here follow the published literature rather than marketing material.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 4963 Da for full-length thymosin beta-4 | Value applies to the parent protein; fragment products may differ |
| Appearance | White to off-white lyophilized powder | Typical form of supplied synthetic peptide |
| Solubility | Freely soluble in water | Polar peptide; dissolves readily in aqueous buffer |
| Storage of dry powder | −20 °C, desiccated, protected from light | Standard laboratory practice for peptides |
| Typical detection method | Liquid chromatography–tandem mass spectrometry | Used in purity testing and anti-doping analysis |
Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.
Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
In November 2013, the FDA lifted its earlier restrictions on rosiglitazone after reviewing the results of the 2009 RECORD clinical trial (a six-year, open-label randomized control trial), which failed to show elevated risk of heart attack or death associated with the medication.
Nicotine is highly addictive but paradoxically has quite weak reinforcing property compared to other drugs of abuse in various animals. Its addictiveness depends on how it is administered and also depends upon the form in which nicotine is used. Animal research suggests that monoamine oxidase inhibitors, acetaldehyde and other constituents in tobacco smoke may enhance its addictiveness. Nicotine dependence involves aspects of both psychological dependence and physical dependence, since discontinuation of extended use has been shown to produce both affective (e.g., anxiety, irritability, craving, anhedonia) and somatic (mild motor dysfunctions such as tremor) withdrawal symptoms. Withdrawal symptoms peak in one to three days and can persist for several weeks. Even though other drugs of dependence can have withdrawal states lasting 6 months or longer, this does not appear to occur with cigarette withdrawal. Normal between-cigarettes discontinuation, in unrestricted smokers, causes mild but measurable nicotine withdrawal symptoms. These include mildly worse mood, stress, anxiety, cognition, and sleep, all of which briefly return to normal with the next cigarette. Smokers have a worse mood than they typically would have if they were not nicotine-dependent; they experience normal moods only immediately after smoking. Nicotine dependence is associated with poor sleep quality and shorter sleep duration among smokers.
== Method == The RAST is a radioimmunoassay test to detect specific IgE antibodies to suspected or known allergens for the purpose of guiding a diagnosis about allergy. IgE is the antibody associated with Type I allergic response: for example, if a person exhibits a high level of IgE directed against pollen, the test may indicate the person is allergic to pollen (or pollen-like) proteins. A person who has outgrown an allergy may still have a positive IgE years after exposure. The suspected allergen is bound to an insoluble material and the patient's serum is added. If the serum contains antibodies to the allergen, those antibodies will bind to the allergen. Radiolabeled anti-human IgE antibody is added where it binds to those IgE antibodies already bound to the insoluble material. The unbound anti-human IgE antibodies are washed away. The amount of radioactivity is proportional to the serum IgE for the allergen. RASTs are often used to test for allergies when:
The age of the Earth is 4.54 Gya as found by radiometric dating of calcium-aluminium-rich inclusions in carbonaceous chrondrite meteorites, the oldest material in the Solar System. Earth, during the Hadean eon (from its formation until 4.031 Gya,) was at first inhospitable to life. During its formation, the Earth lost much of its initial mass, and so lacked the gravity to hold molecular hydrogen and the bulk of the original inert gases. Soon after initial accretion of Earth at 4.48 Gya, its collision with Theia, a hypothesised impactor, is thought to have created the ejected debris that eventually formed the Moon. This impact removed the Earth's primary atmosphere, leaving behind clouds of viscous silicates and carbon dioxide. This unstable atmosphere was short-lived, soon condensing to form the bulk silicate Earth, leaving behind an atmosphere largely consisting of water vapor, nitrogen, and carbon dioxide, with smaller amounts of carbon monoxide, hydrogen, and sulfur compounds. The solution of carbon dioxide in water is thought to have made the seas slightly acidic, with a pH of about 5.5. Condensation to form liquid oceans is theorised to have occurred as early as the Moon-forming impact. This scenario is supported by the dating of 4.404 Gya zircon crystals with high δ18O values from metamorphosed quartzite of Mount Narryer in Western Australia. The Hadean atmosphere has been characterized as a "gigantic, productive outdoor chemical laboratory," similar to volcanic gases today which still support some abiotic chemistry.
== Clinical significance == Deletions and mutations in this gene are associated with supravalvular aortic stenosis (SVAS) and the autosomal dominant cutis laxa. Other associated defects in elastin include Marfan syndrome, emphysema caused by α1-antitrypsin deficiency, atherosclerosis, Buschke–Ollendorff syndrome, Menkes syndrome, pseudoxanthoma elasticum, and Williams syndrome.
Sources: en.wikipedia.org
== Usefulness of NTX as a biomarker == Evaluating an individual's rate of bone turnover, termed bone remodeling, directly may be important in assessing his or her potential nonsurgical treatment response as well as evaluating his or her risk of developing complications during healing following surgical intervention. To determine an individual's rate of bone turnover, numerous biomarkers are available in the body fluids that can be correlated to this rate, and one such biomarker is NTX. However, while NTX does fluctuate in a very sensitive manner in line with bone resorption patterns, they are not very specific, in that they may vary spontaneously without physiologic intervention. For example, NTX levels may drop by 50% from day to day with no treatment, thus, making NTX levels unconvincing evidence of treatment effect. Conversely, the serum CTX biomarker, described in 2000 by Rosen, appears to be a much more effective and valuable indicator of bone resorption rate.
=== Mechanical properties === The mechanical properties of articular cartilage in load-bearing joints such as the knee and hip have been studied extensively at macro, micro, and nano-scales. These mechanical properties include the response of cartilage in frictional, compressive, shear and tensile loading. Cartilage is resilient and displays viscoelastic properties. Since cartilage has interstitial fluid that is free-moving, it makes the material difficult to test. One of the tests commonly used to overcome this obstacle is a confined compression test, which can be used in either a 'creep' or 'relaxation' mode. In creep mode, the tissue displacement is measured as a function of time under a constant load, and in relaxation mode, the force is measured as a function of time under constant displacement. During this mode, the deformation of the tissue has two main regions. In the first region, the displacement is rapid due to the initial flow of fluid out of the cartilage, and in the second region, the displacement slows down to an eventual constant equilibrium value. Under the commonly used loading conditions, the equilibrium displacement can take hours to reach. In both the creep mode and the relaxation mode of a confined compression test, a disc of cartilage is placed in an impervious, fluid-filled container and covered with a porous plate that restricts the flow of interstitial fluid to the vertical direction.
A synthetic, radioactive element, curium is a hard, dense metal with a silvery-white appearance and physical and chemical properties resembling gadolinium. Its melting point of 1344 °C is significantly higher than that of the previous elements neptunium (637 °C), plutonium (639 °C) and americium (1176 °C). In comparison, gadolinium melts at 1312 °C. Curium boils at 3556 °C. With a density of 13.52 g/cm3, curium is lighter than neptunium (20.45 g/cm3) and plutonium (19.8 g/cm3), but heavier than most other metals. Of two crystalline forms of curium, α-Cm is more stable at ambient conditions. It has a hexagonal symmetry, space group P63/mmc, lattice parameters a = 365 pm and c = 1182 pm, and four formula units per unit cell. The crystal consists of double-hexagonal close packing with the layer sequence ABAC and so is isotypic with α-lanthanum. At pressure >23 GPa, at room temperature, α-Cm becomes β-Cm, which has face-centered cubic symmetry, space group Fm3m and lattice constant a = 493 pm. On further compression to 43 GPa, curium becomes an orthorhombic γ-Cm structure similar to α-uranium, with no further transitions observed up to 52 GPa. These three curium phases are also called Cm I, II and III. Curium has peculiar magnetic properties. Its neighbor element americium shows no deviation from Curie-Weiss paramagnetism in the entire temperature range, but α-Cm transforms to an antiferromagnetic state upon cooling to 65–52 K, and β-Cm exhibits a ferrimagnetic transition at ~205 K.
During the events of the crossover film Tokusou Sentai Dekaranger vs. Abaranger, Trinoid #0 Saunaginnan resurrects Ben G, who is subsequently killed by Deka Master, Pink, and Break, as well as Abare Killer. Ben G is voiced by Nobuyuki Hiyama (檜山 修之, Hiyama Nobuyuki). Cristonian Ferley (クリスト星人ファーリー, Kurisuto Seijin Fārī): A werewolf/vampire bat–themed criminal from Planet Cristo who is charged with burglary and murdering several S.P.D. officers. As his body is photosensitive, he tasks a Batsuroid with piloting a Kaijuki called Devil Capture 4 (デビルキャプチャー4, Debiru Kyapuchā Fō) to distract the Dekarangers while Ferley locates and eats a mineral called Lunar Metal so he can roam freely in daylight. Devil Capture 4 is destroyed by Dekaranger Robo while Ferley is deleted by the Dekarangers via the D-Bazooka. In the direct-to-video special Tokusou Sentai Dekaranger Super Video: Super Finisher Match! Deka Red vs. Deka Break, a variation of Ferley called Burning Ferley (バーニング・ファーリー, Bāningu Fārī) appears as part of a simulation training session. Ferley is voiced by Hisao Egawa (江川 央生, Egawa Hisao). Titarnian Metiussl (ティタン星人メテウス, Titan Seijin Meteusu): A brutal flame/astronaut–themed criminal and self-proclaimed "Destroyer King" (破壊王, Hakaiō) from Planet Titarn who seeks out an android girl named Flora, whom he created to control his giant creation Machine Monster Gigas (マシンモンスター・ギーガス, Mashin Monsutā Gīgasu). He tasks a Batsuroid with piloting a gladiator-themed Kaijuki called Cannon Gladiator (キャノングラディエーター, Kyanon Guradiētā) and attacking the Deka Base while he locates Flora.
Sources: en.wikipedia.org
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.
No. No major regulatory authority lists an approved product under this name, and no pharmacopoeial monograph exists for it. Material sold under the label is therefore supplied outside approved pharmaceutical channels, which affects the quality documentation available.
It falls within a prohibited class covering peptide hormones and growth factors, based on presumed effects on tissue repair and blood vessel formation. Anti-doping laboratories have published mass spectrometry methods for detecting thymosin beta-4 related peptides in urine samples.
Usually not, though usage overlaps. The label most often refers to a short acetylated fragment of the parent protein, while thymosin beta-4 itself is the full 43-residue molecule. Because suppliers vary, a sequence statement is needed to settle the question for any particular lot.